- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07277699
Effects of Otago and Frenkel's Exercises on Strengthening of Antigravity Muscles in Parkinson's Disease.
November 29, 2025 updated by: University of Lahore
Using both Otago and Frenkel's exercises offers complementary benefits building muscle strength and refining coordination in anti-gravity muscles making daily activities safer and more fluid for people with Parkinson's.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Combining Otago and Frenkel's exercises can slow functional decline, reduce falls, and improve quality of life for Parkinson's patients.
These programs empower patients and families by promoting active participation in care rather than relying only on medications.
Early introduction, guided by physiotherapists, gives the best outcomes helping patients stay mobile, confident, and independent for longer.
Study Type
Interventional
Enrollment (Actual)
40
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Punjab Province
-
Gujranwala, Punjab Province, Pakistan, 50250
- University of Lahore
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Patient diagnosed with parkinsons disease using the Hoehn and Yahr scale
- Patient age 55-75.
- Both male and female.
- Able to walk independently.
- Willing and ability to provide information consent to participate in study. -
Exclusion Criteria:
- Presence of other neurological condition(stroke, multiple sclerosis).
- severe cardiovascular disease.
- major psychiatric disorder.
- currently participating in other study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Otago Exercise Program
20 Participants in this arm will undergo a combined exercise program consisting of the Otago Exercise Program (OEP) and conventional Physiotherapy.
The intervention is designed to strengthen antigravity muscles (hip, knee, and trunk extensors), improve balance, coordination, and functional mobility, and reduce fall risk in patients with Parkinson's disease.
|
After collecting the patient's data appropriate modalities will be applied to initiate the treatment session.
This includes the use of an Electric Heating pad on the lower limb for 10 mints.
Gentle walking will be performed for 1 mints along with arm swing (10 repetitions) and neck stretching focusing on upper trapezius muscle (3 repetition).After that the12 steps of Otago exercise will be performed with 10 repetition.Total session time is 40 mints.
|
|
Experimental: Frenkel's Exercise Program
20 Participants in this arm will under go Frenkel's Exercises program and conventional physiotherapy.
This intervention help Parkinsons patient by improving coordination, balance and enhance motor learning and confidence
|
After collecting the patient's data sessions will be delivered 3 times per week lasting for 40 mints only and than appropriate modalities will be applied to initiate the treatment session.
This includes the use of an Electric Heating pad on the lower limb for 10 mints.
Gentle walking will be performed for 1 mints along with arm swing (10 repetitions) and neck stretching focusing on upper trapezius muscle (3 repetition).After that the steps of Frenkels exercise program will be performed on patients with 10 repetition.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Antigravity muscle strenght (Manual Muscle strength).
Time Frame: Baseline before treatment (week 0) post -interventiom (week 4 )
|
Strength of major antigravity muscle including Hip muscles, Knee muscles and ankle muscles. strength evaluated by using Manual Muscle Testing based on oxford Grading Scale (0-5). . Grade 0 ( No contraction).
|
Baseline before treatment (week 0) post -interventiom (week 4 )
|
|
Balance and reduction in fall risk.
Time Frame: baseline Before treatment (0 Week) post- intervention ( 4 week )
|
Balance assessed through the Berg Balance Scale (BBS).
Berg Balance Scale items: 14 Tasks (sit to stand, standing, stepping, unsupported, reaching, turning) total score (0-56) scoring:0-4 for each task Maximum score=56 41-56=low Fall risk 21-40=Medium Fall risk 0-20=High Fall risk
|
baseline Before treatment (0 Week) post- intervention ( 4 week )
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 18, 2025
Primary Completion (Actual)
August 18, 2025
Study Completion (Actual)
August 18, 2025
Study Registration Dates
First Submitted
August 26, 2025
First Submitted That Met QC Criteria
November 29, 2025
First Posted (Actual)
December 11, 2025
Study Record Updates
Last Update Posted (Actual)
December 11, 2025
Last Update Submitted That Met QC Criteria
November 29, 2025
Last Verified
August 1, 2025
More Information
Terms related to this study
Other Study ID Numbers
- UOL/IREB/25/09/0051
- UOL (UOL/IREB/25/09/0051)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson
-
Bezmialem Vakif UniversityRecruitingParkinson Disease | Parkinson | Parkinson Disease (PD) | PARKINSON DISEASE (Disorder) | Parkinson s DiseaseTurkey (Türkiye)
-
CND Life SciencesDigestive Disease Associates of CTRecruitingParkinson Disease | Parkinson | PARKINSON DISEASE (Disorder) | Parkinson s DiseaseUnited States
-
Neuron23 Inc.Roche Diagnostic Ltd.; Qiagen Manchester LimitedRecruitingParkinson Disease | Parkinson | Idiopathic Parkinson Disease | Parkinson Disease, Idiopathic | Early Parkinson Disease (Early PD)United States, Spain, Israel, Poland, Italy, United Kingdom
-
National Institute of Neurological Disorders and...Not yet recruiting
-
San Francisco Neurology and Sleep CenterNot yet recruitingPARKINSON DISEASE (Disorder) | Parkinson s DiseaseUnited States
-
Haukeland University HospitalUniversity of Bergen; SPARK NSRecruitingParkinson Disease (PD) | Parkinson s DiseaseNorway
-
CND Life SciencesOregon Health and Science UniversityRecruitingParkinson Disease | Parkinson | Parkinson's Disease and Parkinsonism | PARKINSON DISEASE (Disorder)United States
-
Università degli Studi dell'InsubriaUniversidade Nova de Lisboa; Associazione Parkinson Insubria (AsPI), Section... and other collaboratorsRecruitingParkinson Disease | Parkinson | Parkinson Disease, Idiopathic | PARKINSON DISEASE (Disorder)Italy
-
Danish Research Centre for Magnetic ResonanceUniversity Hospital Bispebjerg and FrederiksbergRecruitingHealthy | Parkinson | Medication AdministrationDenmark
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedParkinson Disease 6, Early-Onset | Parkinson Disease (Autosomal Recessive, Early Onset) 7, Human | Parkinson Disease Autosomal Recessive, Early Onset | Parkinson Disease, Autosomal Recessive Early-Onset, Digenic, Pink1/Dj1United States
Clinical Trials on Otago exercises
-
Riphah International UniversityHealth Education Research Foundation (HERF)RecruitingBalance; DistortedPakistan
-
Foundation University IslamabadCompletedRisk of Fall | Dynamic BalancePakistan
-
Riphah International UniversityRecruiting
-
Riphah International UniversityCompleted
-
Riphah International UniversityRecruiting
-
Riphah International UniversityNot yet recruitingChronic Stroke PatientsPakistan
-
HES-SO Valais-WallisCompletedAccidental FallsSwitzerland
-
Riphah International UniversityEnrolling by invitationParkinson DiseasePakistan
-
Riphah International UniversityCompleted
-
Shifa Tameer-e-Millat UniversityCompleted